

CURRICULUM VITAE

Robert J. Valuck, Ph.D., R.Ph.

Business Address

University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
12850 E. Montview Boulevard, V20-1201
Aurora, Colorado 80045
Telephone: (303) 724-2890
Fax: (303) 724-2627
E-mail: robert.valuck@ucdenver.edu

Home Address

7059 S. Magnolia Circle
Centennial, Colorado 80112
Telephone: (303) 770-1828
E-mail: robert.valuck@comcast.net

EDUCATION

- 1994 Ph.D., Pharmacy (Emphasis in Pharmacy Administration)
University of Illinois at Chicago, Chicago, Illinois
Dissertation: The Effect of Regulatory Controls on the Quality of Psychoactive
Drug Prescribing
- 1992 M.S., Pharmacy (Emphasis in Pharmacy Administration)
University of Illinois at Chicago, Chicago, Illinois
Thesis: Macro-level Screening Criteria to Identify Suboptimal Prescribers of
Controlled Substances
- 1987 B.S., Pharmacy
University of Colorado School of Pharmacy, Denver, Colorado

PROFESSIONAL LICENSURE

- 1989 Registered Pharmacist, State of Illinois (License No. 051-037644)
- 1987 Registered Pharmacist, State of Colorado (License No. 12376)

EMPLOYMENT EXPERIENCE

A. Academic Appointments

2011-present Professor (joint appointment), Department of Epidemiology, Colorado School of Public Health

2009-present Professor (joint appointment), Department of Family Medicine, University of Colorado Denver, School of Medicine

2008-present Professor, Department of Clinical Pharmacy, University of Colorado Denver, School of Pharmacy
Member, Graduate Faculty, Department of Pharmaceutical Sciences, University of Colorado Denver

Current teaching assignments:

Ph.D. Curriculum in Pharmaceutical Outcomes Research

- PHSC7615/EPID7615: Pharmacoepidemiology (Course Director, Instructor)
- PHSC7570: Special Topics in Pharmaceutical Outcomes Research (Instructor)
- PHSC7710: Research Practicum (Course Director, Instructor)

Pharm.D. Curriculum (Entry-level program)

- PHRD6400: Clinical Biostatistics (Course Director, Instructor)
- PHRD4550/PRMD6000: Ethics in the Health Professions (Group facilitator)
- PHRD6150: Professional Skills Development IV (Guest lecturer)

2006-present Guest Lecturer, Department of Preventive Medicine and Biometrics, University of Colorado School of Medicine (topic: Introduction to Pharmacoepidemiology)

2001-2008 Associate Professor, Department of Clinical Pharmacy, University of Colorado Denver, School of Pharmacy; and Member, Graduate Faculty, Department of Pharmaceutical Sciences, University of Colorado Denver

1998-2003 Guest Lecturer, Primary Care Residency Program, University of Colorado School of Medicine (topic: Critical Appraisal of Published Drug Studies).

1996-present Member, Graduate College, University of Colorado Denver

1994-2001 Assistant Professor, Department of Pharmacy Practice, University of Colorado Denver, School of Pharmacy; and Member, Graduate Faculty, Department of Pharmaceutical Sciences, University of Colorado Denver

1994-2000 Previous courses taught at UCHSC School of Pharmacy:

Ph.D. Curriculum in Pharmaceutical Outcomes Research

- Research Methods for Pharmaceutical Outcomes Research (Instructor)
- Data Analysis for Pharmaceutical Outcomes Research (Instructor)
- Database Research Methods (Instructor)

Pharm.D. Curriculum (Entry-level program)

- Evidence-based Pharmacy Practice (Course Director, Instructor)
- Introduction to Clinical Research Methodology I and II (Instructor)

B.S., Pharmacy Curriculum

- Pharmacy and Health Care (instructor)
- Pharmacy Systems and Drug Use Management (Course Director, Instructor)
- Pharmacy Law and Professional Ethics (Course Director, Guest lecturer)

B. Graduate Research Assistantships

- 1991-1994 Graduate Research Assistant, UIC College of Pharmacy
- "Factors Influencing Prescribing Decisions in a Managed Care Setting" (co-Investigator)
 - "Meta-Analysis: Effects of Drug Therapy on Patients' Quality of Life (co-Investigator)
 - "Development and Validation of Behaviorally-Anchored Rating Scales for Student Evaluation of Pharmacy Instruction" (Project Director)
 - "Readership and Journal Preferences of Pharmacists in Illinois" (co-PI)

C. Consulting (past five years' activity only)

- 2008-2010 H. Lundbeck A/S
 2008-2010 Forest Research Institute, Inc.
 2005-2010 Eli Lilly and Company, Inc.
 2004-present Medical-legal consulting (various attorneys, law firms)
 1999-2008 Thomson-Reuters, Inc. (Micromedex)

D. Professional

- 1993 - 1994 Clinical Pharmacist (home health care), Cardiac Alliance, Northbrook, Illinois
 1990 - 1993 Clinical Pharmacist (home health care), Critical Care America, Elk Grove, Illinois
 1989 - 1993 Registry Pharmacist, Pharmstaff, Inc., Chicago, Illinois
 1988 - 1989 Decentralized Pharmacist, University Hospital, Denver, Colorado
 1987 - 1988 Pharmacy Manager, Watson's Tabor Center Drug, Denver, Colorado
 1987 Pharmacist, Hodel's Drug, Denver, Colorado

GRANTSMANSHIP

A. Funded Grants & Contracts

- 2011 “Colorado Evidence-based Retrospective Drug Utilization Review Program.” Co-Principal Investigator and Analytic Lead (0.10 FTE x 1 year), with Robert Page, Pharm.D. (Co-PI and Clinical Lead) and Gina Moore, Pharm.D. (Co-PI and Education Lead). Funded by: Colorado Department of Health Care Policy and Financing (HCPF). Budget: \$167,923. Funding period: 07/11 – 06/12.
- 2011 “Enhancing Fulfillment Data in Community Practices for Clinical Care and Research.” Co-Investigator (0.05 FTE x 1.5 years), with Michael Kahn, M.D. (Principal Investigator) and others. Funded by: Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH). Budget: \$190,455. Funding period: 9/11 – 03/13.
- 2010 “Scalable Architecture for Federated Therapeutic Inquiries Network (SAFTINet).” Co-Investigator (0.10 FTE x 3 years), with Lisa Schilling, M.D. (Principal Investigator) and others. Funded by: Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH). Budget: \$2,460,053. Funding period: 10/10 – 09/13.
- 2010 “Colorado CER and Safety Scholars Program: Mental Health, CVD, and Methods.” (K12 training program grant). K12 trainee Mentor (0.10 FTE x 3 years) with Anne Libby, Ph.D. (Principal Investigator) and others. Funded by: Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH). Budget: \$1,500,000. Funding period: 07/10 – 06/13.
- 2009 “A Cardiovascular Risk Reduction Learning Community in DARTNet.” Co-Investigator (0.10 FTE x 2 years), with Karl Hammermeister, M.D. (Principal Investigator). Funded by: National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), ARRA Challenge Grants program. Budget: \$1,066,415. Funding period: 09/09 – 08/11.
- 2009 “Predicting the Development of Opioid Abuse or Dependence.” Consultant (0.03 FTE), with Bryan Cochran, University of Montana (Principal Investigator) and others. Funded by: National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). Budget: \$100,000. Funding period: 07/09 – 06/11.
- 2009 “Sedative Hypnotic Use by the Mentally Ill: A Medicaid Prescription Policy Study.” Co-Investigator (0.05 FTE), with Judy Zerzan, M.D. (Principal Investigator). Funded by: National Institute of Mental Health (NIMH), National Institutes of Health (NIH). Budget: \$833,534. Funding period: 07/09 - 06/12.

- 2009 “Comparative Effectiveness and Safety of Depression Treatments in DARTNet Primary Care Practices.” Co-Investigator and Director of Research Core (0.20 FTE x 19 months), with David West, Ph.D. (PI), Wilson Pace, M.D. (Task Order Leader) and others. Funded by: Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH), DEcIDE Network Contract Number HHSA29020050037I-TO4. Budget: \$1,600,000. Funding period: 04/09 - 10/10.
- 2008 “Consortium for the Study of Drug Safety.” Co-Investigator (0.10 FTE x 4 years), with Robert Gibbons, Ph.D., University of Chicago (Principal Investigator). Funded by: National Institute of Mental Health (NIMH), National Institutes of Health (NIH). Budget: \$223,174 (subcontract to Dr. Valuck at UCDenver). Funding period: 7/08 - 6/13 (5 year grant; subcontract runs for years 2-5).
- 2008 “Antidepressant Drug Exposure and Risk of Suicide Attempt: A Focus on Newer Agents.” Principal Investigator (0.60 FTE x 9 months). Funded by: Eli Lilly and Company. Budget: \$523,895. Funding period: 05/08 - 09/10.
- 2007 “The Distributed Ambulatory Research in Therapeutics Network (DARTNet).” Co-Investigator and Director of Research Core (0.20 FTE x 16 months), with David West, PhD (Principal Investigator), Wilson Pace, MD (Task Order Leader) and others. Funded by: Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH), DEcIDE Network Contract Number HHSA29020050037I-TO2. Budget: \$1,350,000. Funding period: 09/07 - 04/09.
- 2007 “Impact of Antidepressant Discontinuation on Risk of Suicide Attempt.” Principal Investigator (0.20 FTE x 14 months). Funded by: American Foundation for Suicide Prevention (AFSP), Distinguished Investigator Grants Program. Budget: \$99,710. Funding period: 07/07 - 08/08.
- 2006 “Evaluating the Impact of Drug Warnings and Consensus Recommendations for Metabolic Testing for Patients Receiving Atypical Antipsychotic Drugs: A Multi-State Medicaid Claims Study.” Co-Investigator (0.15 FTE x 4 months) with Elaine H. Morrato, Dr.PH. (Principal Investigator). Funded by: Pfizer, Inc. Budget: \$89,663. Funding period: 12/06 - 11/07.
- 2006 “Effect of the FDA Black Box Warning (Antidepressants and Suicidality) on Patterns of Depression Care in the U.S. Managed Care Population.” Principal Investigator (0.68 FTE x 8 months). Funded by: Eli Lilly and Company. Budget: \$249,417. Funding period: 4/06 - 11/06.
- 2005 “An Observational Study of the Medical Management of Congestive Heart Failure and the Effectiveness of Isosorbide Dinitrate and Hydralazine.” Project Pharmacoepidemiologist (no salary), with Karl Hammermeister, M.D. (PI) and others. Funded by: Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health. Budget: \$200,000. Funding period: 09/05 - 12/06.

- 2005 "The Colorado DEcIDE (CO-DEcIDE) Center." Co-Investigator (percent effort based on specific Task Orders), with John Steiner, M.D. (Principal Investigator). Funded by: Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH). Budget: TBD (based on specific Task Orders). Funding period: 9/05 - 8/10.
- 2005 "Effect of Tier Placement of Duloxetine on Medication Adherence, Healthcare Utilization, and Expenditures." Co-Investigator (0.05 FTE) with Kavita Nair, Ph.D. (Principal Investigator). Funded by: Eli Lilly and Co. Budget: \$77,415. Funding period: 9/05 - 6/06.
- 2004 "Planning Grant for a Prescription Drug Monitoring Program in Colorado." Co-Principal Investigator (no salary offset), with Jody Gingery, M.Ed., R.N., and Susan Warren, J.D., M.P.H. Funded by: U.S. Department of Justice, Office of Justice Programs (OJP), Bureau of Justice Assistance (BJA). Budget: \$50,000. Funding period: 07/04 - 06/05.
- 2003 "Atypical Antipsychotic Treatment Patterns in a Multi-state Medicaid Population." Principal Investigator (0.30 FTE), with various co-investigators. Funded by: Janssen Pharmaceutica LP. Budget: \$129,780. Funding period: 01/04 - 12/05.
- 2003 "The Impact of Cost Sharing on Medication Compliance, Medical Utilization, and Patient Satisfaction." Co-investigator (0.10 FTE), with Patrick Sullivan, Ph.D. (Principal Investigator). Funded by: Pfizer, Inc. Budget: \$98,826. Funding period: 12/03 - 09/04.
- 2003 "The Societal Cost of GI Adverse Events Associated with Current Utilization of Aspirin and NSAIDs in the United States." Co-investigator (0.08 FTE), with Patrick Sullivan, Ph.D. (Principal Investigator). Funded by: Pfizer, Inc. Budget: \$49,354. Funding period: 12/03 - 07/04.
- 2003 "Demonstrating a Return on Investment for Micromedex Products: A Case Study." Co-Principal Investigator (0.05 FTE), with Kavita Nair, Ph.D. Funded by: Thomson Micromedex, Inc. Budget: \$29,792. Funding period: 10/03 - 04/04.
- 2003 "Incidence, Treatment Patterns, and Costs of SRI-related Side Effects." Principal Investigator (0.50 FTE), with Patrick Sullivan, Ph.D. and Joseph Saseen, PharmD. (co-investigators). Funded by: Forest Laboratories, Inc. Budget: \$321,706. Funding period: 03/03 - 12/03.
- 2003 "Absorption of Oral Vitamin B-12 in Older Outpatients with Omeprazole-induced Gastric Acid Suppression." Co-investigator/Statistician (0.01 FTE), with J. Mark Ruscin, Pharm.D. (Principal Investigator). Funded by: University of Colorado Center for Human Nutrition. Budget: \$44,663. Funding period: 01/03 - 12/04.

- 2002 "Incidence of Drug Induced Liver Injury." Co-Investigator (0.05 FTE), with K. Arnold Chan, M.D. (Principal Investigator), and Marsha A. Raebel, Pharm.D. (local site PI). Funded by: National Institute of Diabetes & Digestive & Kidney Diseases (NIDDKD), National Institutes of Health. Budget: \$120,939 (site portion), \$14,136 subcontract to Dr. Valuck. Funding period: 11/02 - 9/04.
- 2000 "Residency in Managed Care Pharmaceutical Outcomes Research." Co-Preceptor (no salary offset). Training Site: Anthem-Blue Cross Blue Shield. Funded by: Pfizer, Inc., and Pharmacia, Inc. Budget: \$30,837. Funding period: 2000 - 01.
- 2000 "Retrospective Claims Database Analysis of Cholesterol Management in a Managed Care Population." Principal Investigator (0.20 FTE). Funded by the Quality Care Research Fund. Budget: \$57,980. Funding period: 12/00 - 5/01.
- 2000 "Evaluating the Effects of Multi-tiered Pharmacy Benefits on Patient Purchasing Behavior." Co-Investigator (0.20 FTE). Funded by the Quality Care Research Fund. Budget: \$198,103. Funding period: 9/00 - 6/02.
- 1999 "Patient Profiling and Provider Feedback to Reduce Adverse Drug Events" (SAF 98144-1). Consultant. Funded by: VA Health Services Research & Development (HSR&D) Program. Budget: \$540,000. Funding period: 1/00 - 2/02.
- 1999 "Colorado Medicaid Antiviral Drug Use Review (DUR) Project." Co-Principal Investigator (0.05 FTE). Funded by: Glaxo Wellcome, Inc. Budget: \$5,000. Funding period: 12/99-5/00.
- 1999 "Patterns of SSRI Prescribing and Use in a Managed Care Population." Principal Investigator (0.25 FTE). Funded by: Pharmacia & Upjohn. Budget: \$44,500. Funding period: 12/99 - 5/00.
- 1999 Continuing Education program development contract: "Urinary Incontinence and Overactive Bladder: A Comprehensive Approach." Program Chair. Funded by: Pharmacia & Upjohn. Budget: \$9,280. Funding period: 9/99 - 12/99.
- 1999 "Development and Testing of CliniMED Computer Software System." Principal Investigator (no salary offset). Funded by: Pharmacia & Upjohn. Budget: \$58,000. Funding period: 6/99 - 5/01.
- 1999 "Use of Selective Serotonin Reuptake Inhibitors in Veterans Affairs Medical Centers." Co-Principal Investigator (0.05 FTE). Funded by: Pharmacia & Upjohn. Budget: \$14,500. Funding period: 6/99 - 11/99.
- 1998 "Development, Implementation, and Validation of an Integrated Computer Application for Clinical Decision Support for Hypertension Patients in the VA Medical System." Co-Principal Investigator (no salary offset). Funded by: Astra Merck, Inc. Budget: \$13,900. Funding period: 7/98 - 6/99.

- 1998 "Treatment Patterns in a Medicaid HIV Population: Guidelines Achievement and Health Systems Implications." Co-Principal Investigator (no salary offset). Funded by: Glaxo Wellcome, Inc. Budget: \$50,000. Funding period: 3/98 - 12/98.
- 1997 "H. Pylori Treatment Patterns in the Colorado Medicaid Population." Co-Principal Investigator (no salary offset). Funded by Astra Merck, Inc. Budget: \$8,900. Funding period: 1/98 - 12/98.
- 1997 "Protease Inhibitors: Patterns of Use, Therapy Conversion, and Adverse Events in the Colorado Medicaid Population." Principal Investigator (no salary offset). Funded by Agouron Pharma. Budget: \$6,055. Funding period: 12/97- 2/98.
- 1997 "Evaluation of In-Person Versus Computer-Mediated Small Group Learning in a Web-based Doctor of Pharmacy Class." Principal Investigator (no salary offset). Funded by the UCHSC Bridge to the Future Innovations in Education MiniGrant Program. Budget: \$4,000. Funding period: 1997-1998.
- 1997 "Development of Drug Specific Drug-Drug Interaction D.U.R. Criteria." Principal Investigator (0.25 FTE). Funded by the United States Pharmacopeial Convention (USP), Inc. Budget: \$150,000. Funding period: 2/1/97 - 5/31/98.
- 1996 "Using Computerized Decision Support to Promote Adherence to Pharmacotherapy Guidelines for Drug Treatment of Hyperlipidemias in Veterans." Principal Investigator (no salary offset). Funded by Pharmacia & Upjohn. Budget: \$18,100. Funding period: 1996-1998.
- 1996 "Serzone Drug Use Evaluation in the Colorado Medicaid Population." Principal Investigator (no salary offset). Funded by Bristol-Myers Squibb. Budget: \$1,500. Funding period: 1996-1997.
- 1996 "Development and Implementation of a Web-Based Course in *Evidence-Based Pharmacy Practice* within the Pharm.D. Program." Principal Investigator (no salary offset). Funded by the UCHSC Bridge to the Future Innovations in Education MiniGrant Program. Budget: \$4,950. Funding period: 1996-1998.
- 1996 "The Effect of Clinical Pharmacy Services on Patient Care, Outcomes, and Costs in Two University Hospital Outpatient Clinics." Co-Investigator (no salary offset). Funded by the University Hospital Education and Research Committee Grants Program. Budget: \$27,500. Funding period: 1996-1998.
- 1996 "Evaluating the Outcomes of Pharmaceutical Care Services in a Managed Care Setting." Co-Investigator (no salary offset). Funded by the Department of Pharmacy Practice, University of Colorado School of Pharmacy. Budget: \$5,000. Funding period: 1996-1997.

- 1996 First Rocky Mountain Regional D.U.R. Symposium: "Drug Formularies - Implications for Access, Cost, and Quality of Care", Aug 23-25, 1996. Program Organizer/Chair (no salary offset). Funded by: Astra-Merck. Budget: \$37,500.
- 1995 "Colorado Medicaid Program Cost of Dispensing Study." Co-Principal Investigator (0.60 FTE). Funded by the State of Colorado, Department of Health Care Policy & Financing. Budget: \$37,447. Funding period: 4/1-6/30, 1996.
- 1995 "Implementation of Pharmaceutical Care in Veterans Affairs Medical Centers Utilizing Managed Care Principles." Co-Investigator (0.15 FTE). Funded by the Department of Veterans Affairs Research Steering Committee and Pharmacia & Upjohn, Inc. Budget: \$523,285. Funding period: 1996-1998.
- 1995 "Evaluation of a Heparin Titration Nomogram on Patient Outcomes at University Hospital (UH)." Co-Investigator (no salary offset). Funded by the UH Education and Research Committee. Budget: \$17,500. Funding period: 1996-1999.
- 1996 "Using Computerized Decision Support to Promote Adherence to Pharmacotherapy Guidelines for Drug Treatment of Hyperlipidemias in Veterans." Principal Investigator (no salary offset). Funded by Pharmacia & Upjohn. Budget: \$18,100. Funding period: 1996-1998.

B. Fellowship / Training support (for self and students/trainees/mentees)

- 2009 Colorado Clinical and Translational Science Institute (CCTSI) "Pharmaco-Epidemiology Training Program" seed funding, \$34,000. Support for one trainee (Heather Orton, Ph.D.), and salary support for self for program development and mentorship (0.20 FTE x 3 months; equivalent to 0.05 FTE x 12 months).
- 2008 American Foundation for Pharmaceutical Education (AFPE) "Gateway to Research" Scholarship (for student mentee: Angela Luetters), 2008-2009, \$5,000.
- 1994 American Foundation for Pharmaceutical Education (AFPE) "Springboard to Teaching" Fellowship (for self), 1994-1996, \$15,000.
- 1993 Upjohn Company Clinical Research Grant, \$1,500 (dissertation support, for self).

PUBLICATIONS

A. Articles

Schumock G.T., Gibbons R.D., Lee T.A., Joo M.J., Stayner L.T., and **Valuck R.J.** The Association Between Leukotriene-Modifying Agents and Spontaneously Reported Suicide. *Drug Information Journal* 2012; 46:99-106.

Anderson H.D., Pace W.D., Libby, AM., West D.R., and **Valuck R.J.** Rates of 5 Common Antidepressant Side Effects Among New Adult and Adolescent Cases of Depression: A Retrospective U.S. Claims Study. *Clinical Therapeutics* 2011; online ahead of print (published December 16, 2011).

Shumock G., Gibbons R., Lee T., Joo M., **Valuck R.J.**, and Stayner L. Relationship Between Leukotriene-modifying Agent Prescriptions Dispensed and Rate of Suicide Deaths by County in the U.S. *Drug, Healthcare and Patient Safety* 2011; 3:1-6.

Sanglier T., Saragoussi D., Milea D., Auray J.P., **Valuck R.J.**, and Tournier M. The Treatment of Major Depressive Disorder Differs Between Elderly People and Younger Adults: Impact of Medicare Part D. *J Am Geriatr Society (JAGS)* 2011; 59:1197-1205.

Shumock G., Lee T., Joo M., **Valuck R.J.**, Stayner L., and Gibbons R. Association Between Leukotriene Modifying Agents and Suicide: What is the Evidence? *Drug Safety* 2011; 34(7):533-544.

Henderson K.C., Hindman J., Johnson S.C., **Valuck, R.J.**, and Kiser J.J. Assessing the Effectiveness of Pharmacy-Based Adherence Interventions on Antiretroviral Adherence in Persons with HIV. *AIDS Patient Care and STDs* 2011; 25(4):221-228.

Morrato E.H., Druss B.G., Hartung D.M., **Valuck R.J.**, Thomas D., Allen R., Campagna E., and Newcomer J.W. Small Area Variation and Geographic and Patient-specific Determinants of Metabolic Testing in Antipsychotic Users. *Pharmacoepidemiology and Drug Safety* 2010; 19:1-10.

Libby A.M., Pace W., Anderson H.O., Bryan C., Ellis S., Allen R.R., Brandt E., West D., and **Valuck R.J.** Comparative Effectiveness Research in DARTNet Primary Care Practices: Point of Care Data Collection on Hypoglycemia and Over-the-Counter and Herbal Use among Patients Diagnosed with Diabetes. *Medical Care* 2010; 48:S39-S44.

Morrato E.H., Nicol G.E., Maahs D., Druss B.G., Hartung D.M., **Valuck R.J.**, Campagna E., and Newcomer J.W. Metabolic Screening in Children Receiving Antipsychotic Drug Treatment. *Archives of Pediatric and Adolescent Medicine* 2010; 164(4):344-351.

Reiter, P.D., Huff, A.D, Knupp, K.G., and **Valuck, R.J.** Intravenous Levetiracetam in the Management of Acute Seizures in Children. *Pediatric Neurology* 2010; 43:117-121.

Morrato E.H., Druss B., Hartung D.M., **Valuck R.J.**, Allen R., Campagna E., and Newcomer J.W. Metabolic Testing Rates in 3 State Medicaid Programs After FDA Warnings and ADA/APA Recommendations for Second-Generation Antipsychotic Drugs. *Archives of General Psychiatry* 2010; 67(1):17-24.

Pace, W.D., Cifuentes, M., **Valuck, R.J.**, et al. An Electronic Practice-Based Research Network for Observational Comparative Effectiveness Research. *Annals of Internal Medicine* 2009; 151:1-3.

Valuck, R.J., Orton, H.D., and Libby, A.M. Antidepressant Discontinuation and Risk of Suicide Attempt: A Retrospective, Nested Case-Control Study. *Journal of Clinical Psychiatry* 2009; 70(8):1069-1077.

Pace, W., West, D., **Valuck, R.**, et al. Distributed Ambulatory Research in Therapeutics Network (DARTNet): Summary Report. (Prepared by University of Colorado DEcIDE Center under contract number HHS-29020050037I-TO2). Rockville, MD: Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH), July 2009. Available at: effectivehealthcare.ahrq.gov/reports/final.cfm. [Peer-reviewed, published report of DEcIDE Center DARTNet grant]

Libby, A.M., Orton, H.D., and **Valuck, R.J.** Persisting Decline in Depression Treatment After FDA Warnings. *Archives of General Psychiatry* 2009; 66(6):633-639.

Hammermeister, K.E., Fairclough, D., Emsermann, C.B., Hamman, R., Ho, M., Phibbs, S., Plomondon, M., **Valuck, R.**, West, D., and Steiner, J.F. Effectiveness of Hydralazine/Isosorbide Dinitrate in Racial/Ethnic Subgroups with Heart Failure. *Clinical Therapeutics* 2009; 31:632-643.

Williams-Skipp, C., Raman, T., **Valuck, R.J.**, Watkins, H., Palmer, B.E., and Scheinman, R.I. Unmasking of a Protective Tumor Necrosis Factor Receptor I-Mediated Signal in the Collagen-Induced Arthritis Model. *Arthritis & Rheumatism* 2009; 60:408-418.

Morrato, E.H., Newcomer, J.W., Allen, R., and **Valuck, R.J.** Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs: A Retrospective, Population Based Study of Medicaid Claims Data. *Journal of Clinical Psychiatry* 2008; 69:316-322.

Morrato, E.H., Libby, A.M., Orton, H.D., deGruy III, F.V., Brent, D.A., Allen, R., and **Valuck, R.J.** Frequency of Provider Contact After FDA Advisory on Risk of Pediatric Suicidality with SSRIs. *American Journal of Psychiatry* 2008; 165:42-50.

Valuck, R.J., Libby, A.M., Benton, T., and Evans, D.L. A Descriptive Analysis of 10,000 Suicide Attempters in United States Managed Care Plans, 1998-2005. *Primary Psychiatry* 2007; 14(11):52-60.

- Valuck, R.J.**, Morrato, E.H., Dodd, S., Oderda, G., Haxby, D.G., and Allen, R. How Expensive is Antipsychotic Polypharmacy? Experience from Five US State Medicaid Programs. *Current Medical Research and Opinion* 2007; 23(10):2567-2576.
- Valuck, R.J.**, Libby, A.M., Orton, H.D., Morrato, E.H., Allen, R., and Baldessarini, R.J. Spillover Effects on Treatment of Adult Depression in Primary Care After FDA Advisory on Risk of Pediatric Suicidality With SSRIs. *American Journal of Psychiatry* 2007; 164:1198-1205.
- McClure, D.L., **Valuck, R.J.**, Glanz, M., Murphy, J.R., and Hokanson, J.E. Statin and Statin/Fibrate Use Were Significantly Associated With Increased Myositis Risk in a Managed Care Population. *Journal of Clinical Epidemiology* 2007; 60:812-818.
- Baldessarini, R.J., Tondo, L., Strombom, I.M., Dominguez, S., Fawcett, J., Licinio, J., Oquendo, M.A., Tollefson, G.D., **Valuck, R.J.**, and Tohen, M. Ecological Studies of Antidepressant Treatment and Suicidal Risks. *Harvard Review of Psychiatry* 2007; 15(4):133-145.
- Glassman, P.A., Balperio, P., Lanto, A., Simon, B., **Valuck, R.**, Sayers, J., and Lee, M. The Utility of Adding Retrospective Medication Profiling to Computerized Provider Order Entry in an Ambulatory Care Population. *Journal of the American Medical Informatics Association (JAMIA)* 2007; 14:424-431.
- Reiter, P.D., **Valuck, R.J.**, and Taylor, R.S. Evaluation of Off-label Recombinant Activated Factor VII for Multiple Indications in Children. *Clinical Applied Thrombosis and Hemostasis* 2007; 13(3):233-240.
- Libby, A.M., Brent, D.A., Morrato, E.H., Orton, H.D., Allen, R., and **Valuck, R.J.** Decline in Treatment of Pediatric Depression After FDA Advisory on Risk of Suicidality with SSRIs. *American Journal of Psychiatry* 2007; 164:884-891. [lead article]
- McClure, D.L., **Valuck, R.J.**, Glanz, M., and Hokanson, J.E. Systematic Review and Meta-Analysis of Clinically Relevant Adverse Events from HMG CoA Reductase Inhibitor Trials Worldwide from 1982-Present. *Pharmacoepidemiol Drug Safe.* 2007; 16:132-143.
- Morrato, E.H., Dodd, S., Oderda, G., Haxby, D.G., Allen, R.R., and **Valuck, R.J.** on behalf of the Medicaid Pharmacotherapy Research Consortium. Prevalence, Utilization Patterns, and Predictors of Antipsychotic Polypharmacy: Experience in a Multistate Medicaid Population, 1998-2003. *Clinical Therapeutics* 2007; 29(1): 183-195.
- Reiter, P.D., Novak, K., **Valuck, R.J.**, Rosenberg, A.A., and Fish, D. Effect of a Closed Drug-Delivery System on the Incidence of Nosocomial and Catheter-Related Bloodstream Infections in Infants. *Epidemiology and Infection* 2006; 134(2):285-291.
- Davidson, J., Nair, K.V., **Valuck, R.J.**, and Moore, G. Evidence-Based Medicine in the Pharmacy. *Patient Safety & Quality Healthcare* 2006; Mar/Apr: 46-49.

- Saseen J.J., Williams, S.A., **Valuck, R.J.**, O'Donnell, J.C., and McDonough, K. The Performance Gap between Clinical Trials and Patient Treatment for Dyslipidemia: A Comprehensive Review. *Disease Management & Health Outcomes* 2005; 13(4):255-265.
- Nair, K.V., **Valuck, R.J.**, Allen, R.R., and Lewis, S.J. Impact of Increased Copayments on the Discontinuation/Switching Rates of Nonformulary Medications. *Journal of Pharmaceutical Technology* 2005; 21:137-143.
- Sullivan, P.W., **Valuck, R.**, Brixner, D.I., and Armstrong, E.P. Managed Care's Response to a Pharmacoeconomic Model of Serotonin Reuptake Inhibitors. *Pharmacy and Therapeutics (P&T)* 2005; 30(3):178-182.
- Sullivan, P.W., **Valuck, R.**, Brixner, D.I., and Armstrong, E.P. A Pharmacoeconomic Model for Making Value-Based Decisions About Serotonin Reuptake Inhibitors. *Pharmacy and Therapeutics (P&T)* 2005;30(2):96-106.
- Reiter, P.D., Rosenberg, A.A., **Valuck, R.**, and Novak, K. Effect of Short-Term Erythropoietin Therapy in Premature Infants. *Journal of Perinatology* 2005;25(2):125-129.
- Valuck, R.J.**, Libby, A.M., Sills, M.R., et al. Antidepressant Treatment and Risk of Suicide Attempt by Adolescents with Major Depressive Disorder: A Propensity-adjusted Retrospective Cohort Study. *CNS Drugs* 2004; 18(15):1119-1132.
- Sullivan, P.W., **Valuck, R.**, Saseen, J., and MacFall, H.M. A Comparison of the Direct Costs and Cost Effectiveness of Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions. *CNS Drugs* 2004; 18(13):911-932.
- Nair, K.V., and **Valuck, R.J.** Consumer Responses to a Pharmacy Benefit Report Card. *Journal of Health Care Finance* 2004; 31(1):55-72.
- Valuck, R.** Selective Serotonin Reuptake Inhibitors: A Class Review. *Pharmacy and Therapeutics (P&T)* 2004; 29(4):234-243.
- Ganther, J.M., Nair, K.V., **Valuck, R.J.**, McCollum, M., and Lewis, S.J. Consumer Attitudes and Factors Related to Prescription Switching Decisions in Multitier Copayment Drug Benefit Plans. *Am J Manage Care* 2004; 10(3):201-208.
- Valuck R.J.**, and Ruscini, J.M. A Case-Control Study on Adverse Effects: H2-Blocker or Proton Pump Inhibitor Use and Risk of Vitamin B-12 Deficiency in Older Adults. *J Clin Epidemiol* 2004; 57:422-428.
- Nair, K.V., and **Valuck, R.J.** Impact of Three-Tier Pharmacy Benefit Structures on Consumer Attitudes, Pharmacy, Medical Utilization and Costs: A Critical Review. *Disease Management & Health Outcomes* 2004; 12(2):81-92.

- Valuck, R.J.**, Williams, S.A., MacArthur, M., et al. A Retrospective Cohort Study of Correlates of Response to Pharmacologic Therapy for Hyperlipidemia in Members of a Managed Care Organization. *Clinical Therapeutics* 2003;25:2936-2957.
- Reiter, P.D., Sims, C., Harmes, L., Paisley, J., Rosenberg, A.A., and **Valuck, R.J.** Calfactant Sterility in Multiple Doses from Single-Use Vials. *Ann Pharmacother.* 2003; 37:1219-23.
- Nair, K.V., Wolfe, P., **Valuck, R.J.**, McCollum, M., Ganther, J.M., and Lewis, S.J. Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals with Chronic Disease. *J Managed Care Pharm.* 2003;9(2):123-133.
- Nair, K.V., Ganther, J.M., **Valuck, R.J.**, McCollum, M.M., and Lewis, S.J. Impact of Multi-tiered Pharmacy Benefits on Attitudes of Plan Members With Chronic Disease States. *J Managed Care Pharm.* 2002; 8(6):477-91.
- Valuck, R.J.** Treatment of Depression with Citalopram, Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in Managed Care: Part 2—Patient Comorbidities and Coprescribed Therapies. *Drug Benefit Trends* 2002; 14(8):33-40.
- Valuck, R.J.** Treatment of Depression with Citalopram, Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in Managed Care: Part 1—Drug Selection, Dosing, and Utilization. *Drug Benefit Trends* 2002; 14(7):23-30.
- Nair, K.V., Ganther, J.M., **Valuck, R.J.**, McCollum, M., and Lewis, S.J. Improving Formulary Compliance with Managed Care Members. *Drug Benefit Trends* 2002; 14(7):44-46.
- Roose, S.P., Katz, I.R., Pollock, B.G., and **Valuck, R.J.** Contemporary Issues in the Diagnosis and Treatment of Late-life Depression. *J Am Med Dir Assoc.* 2002; 3(4 Suppl):H26-29.
- Ruscini, J.M., Page, R.L., and **Valuck, R.J.** Vitamin B-12 Deficiency Associated with Histamine₂-Receptor Antagonists and a Proton Pump Inhibitor [case report]. *Annals of Pharmacotherapy* 2002; 36:812-6.
- Vander Zanden, J.A., **Valuck, R.J.**, Bunch, C.L., et al. Systemic Adverse Effects of Ophthalmic Beta-Blockers. *Annals of Pharmacotherapy* 2001; 35:1633-7.
- Valuck, R.J.**, Perlman, J.I., Anderson, C., and Wortman, G.I. Co-prescribing of Medications Used to Treat Obstructive Lung Disease, Congestive Heart Failure, and Depression Among Users of Topical Beta Blockers: Estimates from Three U.S. Veterans Affairs Medical Centers. *Pharmacoepidemiology and Drug Safety* 2001; 10:511-516.
- Sherman, D.S., Clarke, S.H., Lefkowitz, J.B., **Valuck, R.**, Lindenfeld, J., and Stringer, K.A. Development, Validation, and Assessment of Compliance of an Institution-Specific Heparin Titration Nomogram. *Pharmacotherapy* 2001; 21:1167-1174.

- Carter, B.L., Malone, D.C., Billups, S.J., **Valuck, R.J.**, Barnette, D.J., Sintek, C.D., et al. Interpreting the Findings of the IMPROVE Study. *Am J Health-Syst Pharm* 2001; 58:1330-7.
- Malone, D.C., Carter, B.L., Billups, S.J., **Valuck, R.J.**, Barnette, D.J., Sintek, C.D., et al. Can Clinical Pharmacists Affect SF-36 Scores in Veterans at High Risk for Medication-Related Problems? *Med Care* 2001; 39:113-122.
- Carter, B.L., Billups, S.J., Malone, D.C., **Valuck, R.J.**, Barnette, D.J., and Sintek, C.D. How to IMPROVE Ambulatory Care: Guidelines for Clinical Pharmacists. *Federal Practitioner* 2001; 18:38-46.
- Ellis, S.L., Carter, B.L., Malone, D.C., Billups, S.J., Okano, G.J., **Valuck, R.J.**, et al. Clinical and Economic Impact of Ambulatory Care Clinical Pharmacists in Management of Dyslipidemia in Older Adults: The IMPROVE Study. *Pharmacotherapy* 2000; 20: 1508-1516.
- Malone, D.C., Carter, B.L., Billups, S.J., **Valuck, R.J.**, Barnette, D.J., Sintek, C.D., et al. An Economic Analysis of a Randomized, Controlled, Multicenter Study of Clinical Pharmacist Interventions for High-Risk Veterans: The IMPROVE Study. *Pharmacotherapy* 2000; 20(10):1149-1158.
- Valuck, R.J.**, Byrns, P.J., Fulda, T.R., Vander Zanden, J., and Parker, S., for the USP Drug Utilization Review Panel. Methodology for Assessing Drug-Drug Interaction Evidence in the Peer-Reviewed Medical Literature. *Curr Ther Research* 2000; 61: 553-568.
- Fulda, T.R., **Valuck, R.J.**, Byrns, P.J., Vander Zanden, J., and Parker, S., for the USP Drug Utilization Review Panel. Disagreement Between Compendia on Inclusion or Rating of Drug-Drug Interactions. *Current Therapeutic Research* 2000; 61(8): 540-548.
- Carter, B.L., Brunson, B.J., Hatfield, C.L., and **Valuck, R.J.** Description of an Introductory Course Designed to Socialize Pharmacy Students. *Am J Pharm Educ* 2000; 64: 166-173.
- Reiter, P.D., Rosenberg, A.A., and **Valuck, R.J.** Factors Associated with Successful Epoetin Alfa Therapy in Premature Infants. *Ann Pharmacother.* 2000; 34:433-39.
- Billups, S.J., Okano, G., Carter, B.L., Malone, D.C., **Valuck, R.J.**, Barnette, D.J., and Sintek, C.D. Assessing the Structure and Process of Delivering Pharmaceutical Care in Veterans Affairs Medical Centers: The IMPROVE Study. *Am J Health-Syst Pharm* 2000;57:29-39.
- Mattei, M.P., **Valuck, R.J.**, Barrett, P.H., and Gonzales, R. Decreasing Antibiotic Use in Ambulatory Practice: Impact and Cost. *Pharmacoeconomics: Infectious Diseases* November 1999; 3(4):4-5.

- Malone, D.C., Billups, S.J., **Valuck, R.J.**, and Carter, B.L., for the IMPROVE Investigators. Development of a Chronic Disease Indicator Score Using a Veterans Affairs Medical Center Medication Database. *J Clin Epidemiol* 1999; 52:551-557.
- Valuck, R.J.**, Perlman, J.I., and Wortman, G.I. The Latest in Ophthalmic Freeware. *Review of Ophthalmology* May 1999; 47-48.
- Carter, B.L., Malone, D.C., **Valuck, R.J.**, et al. The IMPROVE Study: Background and Study Design. *Am J Health-Syst Pharm* 1998; 55:62-67.
- Lambert, B.L., Salmon, J.W., Stubbings, J., Gilomen-Study, G., **Valuck, R.**, Kezlarian, K., et al. Factors Associated with Antibiotic Prescribing in a Managed Care Setting: An Exploratory Investigation. *Social Science & Medicine* 1997; 45:1767-1779.
- Gwyn, B.C., Malone, D.C., **Valuck, R.J.**, and Schafermeyer, K.W. 1996 Colorado Cost of Dispensing Study. *The Colorado Pharmacist* 1997; 28(3):15-17.
- Moore, L., **Valuck, R.**, McDougal, C., and Fink, W. A Comparative Study of One-year Weight Gain Among Users of Medroxyprogesterone Acetate, Levonorgestrel Implants, and Oral Contraceptives. *Contraception* 1995; 52:215-220.
- Grussing, P., **Valuck, R.**, and Williams, R. Development and Validation of Behaviorally-Anchored Rating Scales for Student Evaluation of Pharmacy Instruction. *Am J Pharm Educ* 1994; 58:25-37.
- Valuck, R.**, Poirier, S., and Mrtek, R. Patent Medicine Muckraking: Influences on American Pharmacy, Social Reform, and Foreign Authors. *Pharmacy in History* 1992; 34(4):183-92.
- Valuck, R.**, Grussing, P., and Pilkington, M. Information Services to I.Ph.A. Members. *Illinois Pharmacist* 1992; 54(10):14-18.

B. Book Chapters

Valuck, R.J., and Jackson, B. Chapter 13: Secondary Data Analysis: Commercial Data. In: *Research Methods for Pharmaceutical Practice and Policy*, ed. R. Aparasu. London: Pharmaceutical Press, 2011.

Valuck, R.J., and Nair, K.V. Chapter 5: Drug Use and the Health Care System. In: *Pharmaceutical Care, 2nd Edition*, eds. C.H. Knowlton and R.P. Penna. Bethesda, MD: American Society of Health-System Pharmacists, 2003.

Hansen, D.B., Rifkin, J., and **Valuck, R.J.** Chapter 111: Common Drug Interactions and Toxicity. In: *Primary Care Secrets, 2nd Edition*, ed. J. Mladenovic. Philadelphia: Hanley & Belfus, 1998.

Hatoum, H.T., and **Valuck, R.J.** Chapter 5: Drug Use and the Health Care System. In: *Pharmaceutical Care*, eds. C.H. Knowlton and R.P. Penna. New York: Chapman & Hall, 1996.

C. Published Abstracts

Czaja, A.S., and **Valuck, R.** Off-Label Antidepressant Use in Children, Adolescents, and Young Adults. *Pharmacoepidemiology and Drug Safety* 2011; 20(S1):S315 (No. 726).

Slejko, J.F., **Valuck, R.J.**, Ho, P.M., Anderson, H.D., Nair, K.V., and Campbell, J.D. New Statin Users' Persistence and Adherence: Both are Critical Concepts in the Comprehensive Characterization of Medication Exposure. *Value in Health* 2011; 14:A44 (No. PCV65).

Anderson, H.D., Libby, A.M, Pace, W.D., West, D.R., and **Valuck, R.J.** Differential Rates of Side Effects in Depressed Adults and Adolescents Being Treated with Antidepressants. *Value in Health* 2011; 14:A186 (No. PMH6).

Valuck, R.J., Libby, A.M., Anderson, H.D., Erder, M., Milea, D., Doshi, J.A., Collins, C., and Preskorn, S. Likelihood of Potential Drug-Drug Interactions Among Persons Initiating Therapy with Selective Serotonin Reuptake Inhibitors: Effect of Initial SSRI and Other Factors. *Value in Health* 2011; 14:A186 (No. PMH7).

Sanglier, T., Milea, D., Saragoussi, D., Auray, J.P., Tournier, M., and **Valuck, R.J.** Age Related Differences in Antidepressant Prescribing. *Pharmacoepidemiology and Drug Safety* 2010; 19(S1):S281-S282 (No. 665).

Slejko, J.F., Anderson, H.D., and **Valuck, R.J.** A Decade of Statin Laboratory Test Monitoring in the United States (1997-2007): A Cohort Study. *Value in Health* 2010; 13(3):A156-A157 (No. PCV41).

Slejko, J.F., Libby, A.M., **Valuck, R.J.** Trends in C-Reactive Protein Screening Prior to Statin Use in the United States. *Value in Health* 2010; 13(3):A151 (No. PCV12).

Van Den Bos, J., Perlman, D., Cochran, B.T., Carter, J.T., and **Valuck, R.** Descriptive Understanding of Diagnosed Opioid Misusers versus Other Opioid Users. *Value in Health* 2010; 13(3):A104 (No. PMH3).

Slejko, J.F., Anderson, H.D., and **Valuck, R.J.**, Nair, K.V., and Campbell, J.D. United States PhD Programs in Pharmacoeconomics and Outcomes Research. *Value in Health* 2010; 13(3):A96 (No. PHP81).

Valuck, R.J., Orton, H.D., and Libby, A.M. Antidepressant Discontinuation and Risk of Suicide Attempt. *Pharmacoepidemiology and Drug Safety* 2009; 18(S1):S95 (No. 223).

Morrato, E.H., Druss, B., Hartung, D.M., **Valuck, R.J.**, et al. Determinants of Metabolic Testing for Patients Treated with Second-Generation Antipsychotics after the FDA Diabetes Warning. *Pharmacoepidemiology and Drug Safety* 2009; 18(S1):S100 (No. 233).

Morrato, E.H., Nicol, G., Druss, B., Hartung, D.M., **Valuck, R.J.**, et al. Metabolic Risk Mitigation in Children Receiving Antipsychotics. *Pharmacoepidemiology and Drug Safety* 2009; 18(S1):S181-S182 (No. 418).

Valuck, R.J., Orton, H.D., and Libby, A.M. General Population Risk of Suicide Attempt Compared to Depressed Untreated and Antidepressant Treated Populations. *Pharmacoepidemiology and Drug Safety* 2009; 18(S1):S200-S201 (No. 462).

Libby, A.M., Orton, H.D., and **Valuck, R.J.** Decline in Depression Treatment Persists After FDA Antidepressant Warnings. *Value in Health* 2008; 11(6):A596 (No. PMH51).

Nair, K., Van Den Bos, J., **Valuck, R.J.**, and Draaghtel, K. The Impact of Duloxetine, Venlafaxine, and Escitalopram Use and Prescription Copays on Medication Persistence, HEDIS Measures, and Expenditures. *Value in Health* 2008; 11(3):A126 (No. PMH56).

Morrato, E.H., **Valuck, R.J.**, and Feinleib, M. Characteristics of Nefazodone Patients Receiving Baseline Liver Function Testing. *Pharmacoepidemiology and Drug Safety* 2006; 15(S1):S139 (No. 296).

Morrato, E.H., **Valuck, R.J.**, and Feinleib, M. Changes in Liver Function Testing Following the Nefazodone Boxed Warning. *Pharmacoepidemiology and Drug Safety* 2006; 15(S1):S139-S140 (No. 297).

Valuck, R.J., Morrato, E.H., Dodd, S.L., and Allen, R.R. Antipsychotic Polypharmacy Costs: A Five-State Medicaid Study. *Value in Health* 2006; 9(3):A70-A71 (No. PMH22).

- Valuck, R.J.**, Libby, A.M., Morrato, E.H., Oquendo, M.A., Brown, H., and Gibbons, R.D. Antidepressant Treatment and Risk of Suicide Attempt by Adults with Major Depressive Disorder: A Propensity-Adjusted Retrospective Cohort Study. *Neuropsychopharmacology* 2005; 30(S1):S242-S243 (No.87).
- Valuck, R.J.**, Libby, A.M., and Allen, R.R. Rates and Characteristics of Suicide Attempt Cases among Users of Antidepressants in Managed Care: A Seven-Year Case Series, 1997-2003. *Pharmacoepidemiology and Drug Safety* 2005; 14(S2):S188-S189 (No.378).
- McClure, D.L., **Valuck, R.**, and Hokanson, J.E. Quantifying the Risk of Myositis Associated with HMG CoA Reductase Inhibitor (Statin) Use in a Diverse HMO Population. *Pharmacoepidemiology and Drug Safety* 2005;14(S2):S126 (No.252).
- Morrato, E.H., Feinleib, M., and **Valuck, R.J.** Impact of Nefazodone Relabeling: Changes in Prescriber Mix and Prescribing Volume. *Pharmacoepidemiology and Drug Safety* 2005; 14(S2):S70 (No.138).
- Nair, K.V., and **Valuck, R.J.** Impact of Increased Copayments on Switching and Discontinuation Rates for Non-formulary Medications. *Value in Health* 2005; 8(3):283 (PHP3).
- Morrato, E.H., and **Valuck, R.J.** Impact of Relabeling on Nefazodone Prescribing: A Risk Minimization Evaluation. *Value in Health* 2005; 8(3):395(PMH34).
- Ellis, S.L., Linnebur, S.A., Astroth, J.D., and **Valuck, R.J.** Differences Between Physician, Dentist and Pharmacist Recommendations for Anticoagulation Management in Patients Undergoing Dental Procedures. *Pharmacotherapy* 2004; 24(10):1438 (Abstract #111).
- McClure, D.L., **Valuck, R.**, Glanz, M., and Hokanson, J.E. Hepatic but Not Myopathic Adverse Events Are Significantly Associated with Statin Use: Results from a Meta-Analysis of HMG CoA Reductase Inhibitor Trials Worldwide from 1982 through 2003. *Pharmacoepidemiology and Drug Safety* 2004; 13(S1):S133-134.
- Valuck, R.J.**, Libby, A.M., Sills, M.R., Allen, R.R., and Giese, A.A. Antidepressant Use and Risk of Suicide Attempt in Adolescents with Major Depressive Disorder. *Value in Health* 2004; 7(3):266 (PMH11).
- Stolpman, N.M., **Valuck, R.J.**, Lezotte, D., Malone, D.C., Glazner, J., and Everson, G.T. A Pharmacoeconomic Assessment of the Benefits and Costs of Managing Immunosuppression in Post-Liver Transplant Patients: A University Hospital Perspective. *Value in Health* 2004; 7(3):348-349 (PG18).
- Sullivan, P.W., **Valuck, R.**, Saseen, J., and MacFall, H.M. Direct Costs of Treating an Initial Episode of Depression: A Comparison of the Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions. *J Managed Care Pharm.* 2004; 10(2):182-183.

- Nair, K.V., Wolfe, P., **Valuck, R.J.**, McCollum, M., Ganther, J.M., and Lewis, S.J. Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals with Chronic Disease. *J Managed Care Pharm.* 2003;9(2):190.
- Nair, K., Ganther, J., **Valuck, R.**, McCollum, M., and Lewis, S. Impact of Three-Tiered Pharmacy Benefit Plans on Member Satisfaction, Loyalty, and Willingness-to-Pay. *J Am Pharmaceutical Assoc.* 2003;43(2):306 (No. 159).
- McCollum, M., Page, R.L., Nair, K., and **Valuck, R.J.** Gender Bias in the Use of Beta-Blocker Therapy in Heart Failure Patients. *Pharmacotherapy* 2003;23(3):414 (No. 153).
- Nair, K.V., **Valuck, R.J.**, and Allen, R.R. Rates of Continuation of Non Formulary Medications for Chronic Disease Sufferers in Multi-tiered Pharmacy Benefit Plans. *Value in Health* 2003;6(3):209 (PHP30).
- Valuck, R.J.**, Williams S.A., MacArthur, M., Saseen, J.J., Nair, K., McCollum, M., and Ensor, J. Patterns of Hyperlipidemia Pharmacological Treatment in a Manged Care Organization. *ASHP Midyear Clinical Meeting 2002*; 37(Dec):P-629E.
- Valuck, R.J.**, Williams S.A., MacArthur, M., Saseen, J.J., Nair, K., McCollum, M., and Ensor, J. Determinants of Successful Outcome in Hyperlipidemia Management. *Circulation* 2002; 106(16):20-21.
- Valuck, R.J.**, Nair, K., Wolfe, P., McCollum, M., and Lewis, S. Impact of Multi-tiered Pharmacy Benefits on Medication Adherence. *Value in Health* 2002;5(3):139-40 (PHP5).
- Nair, K.V., Wolfe, P., Ganther, J.M., **Valuck, R.J.**, McCollum, M., and Lewis, S. Impact of Multi-tiered Pharmacy Benefits on Patient Attitudes and Behavior. *Value in Health* 2002; 5(3):143 (PHP14).
- Nair, K.V., Ganther, J.M., **Valuck, R.J.**, McCollum, M., and Lewis, S.J. Impact of Multi-tiered Pharmacy Benefits on Patient Attitudes Regarding Formulary and Nonformulary Medications. *J Managed Care Pharm* 2002; 8(2):116-117.
- Nair, K.V., Ganther, J.M., **Valuck, R.J.**, McCollum, M., and Lewis, S.J. Impact of Multi-tiered Pharmacy Benefits on Patient Attitudes. *J Am Pharm Assoc* 2002; 42(2):138.
- Valuck, R.J.** Drug Selection, Dosing, and Utilization Patterns Among Depressed Patients Treated with SSRI's and Venlafaxine in U.S. Managed Care Plans. *Value in Health* 2001; 4(6):452 (PMH4).
- Valuck, R.J.** Patterns of Comorbidities and Coprescribing Among Depressed Patients Treated with SSRI's and Venlafaxine in U.S. Managed Care Plans. *Value in Health* 2001; 4(6):452 (PMH6).

- Valuck, R.J.** Direct Six-month Costs of Treating Depression with Citalopram, Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in Managed Care. *J Managed Care Pharm* 2001; 7(5): 370-1.
- Valuck, R.J.** Indices for Evaluation of Drug Cost/Utilization: Every Silver Lining Has a Gray Cloud. *Value in Health* 2001; 4(2): 173 (PHP13).
- Nair, K.V., Ganther, J.M., **Valuck, R.J.**, McCollum, M., and Lewis, S.J. Evaluating Patient Attitudes Related to Multi-tiered Pharmacy Benefits. *J Am Pharm Assoc* 2001;41(2):323.
- Gorman, K.E., and **Valuck, R.** Cost-effectiveness of Pharmacist Conducted Patient Discharge Medication Teaching in a Rural Hospital. *ASHP Midyear Clinical Meeting* 2000; 35(Dec):105.
- Sherman, D.S., Clarke, S.H., **Valuck, R.**, Lindenfeld, J., and Stringer, K.A. Development and Validation of a Heparin Titration Nomogram in Heart Failure Patients Admitted to a University Hospital. *Pharmacotherapy* 1999; 19:481.
- Barnette, D.J., May, S.K., Paulsen, S.M., and **Valuck, R.J.** Survey of Faculty Perceptions of Internet-based Teaching Compared to Classroom Teaching. *American Association of Colleges of Pharmacy (ACCP) 100th Annual Meeting* 1999; (Jul):156.
- Valuck, R.J.** Internet-based Doctor of Pharmacy Course (PRDO5240: Evidence Based Pharmacy Practice). *ACCP 99th Annual Meeting* 1998; (Jul):59.
- Valuck, R.J.**, and Altieri, R.J. Comparison of Two Methods for Student Assessment of Instruction. *ACCP 99th Annual Meeting* 1998; (Jul):66.
- Pickard, J., **Valuck, R.**, Borgelt, L., Cavness, J., Rifkin, J., and Mladenovic, J. A Computerized Expert Prescribing System: Effect on Patient Care. *J General Internal Medicine* 1998; 13(Suppl 1):17.
- Ruscin, M., and **Valuck, R.** Low-Normal Serum Vitamin B₁₂ Levels in a Geriatric Primary Care Clinic. *J Am Geriatr Soc* 1998; 46:S107 (No. P363).
- Ruscin, J.M., and **Valuck, R.J.** Chronic Gastric Acid Suppression and Vitamin B₁₂ Deficiency in Older Adults. *Pharmacotherapy* 1998; 18: 431 (No. 32).
- Billups, S., Malone, D., **Valuck, R.**, and Carter, B. Computerized Development of a Chronic Disease Indicator Score Using a Prescription Database. *J Am Pharm Assoc* 1998; NS38(2):263 (No. 113).
- Malone, D.C., **Valuck, R.J.**, Billups, S., and Ruelle, A. Identifying Patients at Risk for Drug-related Problems Using Automated Pharmacy Data. *J Am Pharm Assoc* 1997; NS37(2): 254 (No. 87).

Mancano, M.A., Shubert, J., and **Valuck, R.J.** Utilizing the Drug Usage Evaluation Process to Guide Physician Education and Track Patient Outcome. *ASHP Midyear Clinical Meeting* 1996; 31(Dec):P-542E.

Valuck, R. The Incidence of Psychoactive Drug Prescribing Problems: An Epidemiologic Estimate Using Prescription Claims Data. *Pharmacoepidemiology and Drug Safety* 1995; 4(S1):S31.

D. Other Publications (Editorial work, Letters, C.E. materials, Treatment Guidelines, etc.)

Valuck, R.J., Supplement Editor. Shrinking Health Care Disparities in Women: The Depression Dilemma. *J Managed Care Pharm* 2007; 12(9 Suppl A):S1-S30.

Valuck, R.J., Supplement Editor. Burden of Illness: Costs & Consequences of Our Fragmented Mental Health Care System. *J Managed Care Pharm* 2006; 12(2 Suppl):S1-S40.

Valuck, R.J., Supplement Editor. Depression in Corporate America: An Integrated Care Approach to Increase Productivity and Improve Outcomes. *J Managed Care Pharm* 2005; 11(3 Suppl):S1-S23.

Valuck, R. Letter to the Editor of the *American Journal of Managed Care*, in reference to article by Cox et al. [*Am J Manag Care* 2003; 9:785]. *Am J Manag Care* 2004; 10:285.

Valuck, R. Letter to the Editor of the *Journal of Managed Care Pharmacy*, in reference to article by Tucker et al. [*J Managed Care Pharm* 2001; 7:224]. *J Managed Care Pharm* 2001; 7:338.

Granville, L., Lipsky, M., MacDiarmid, S., Newman, D., **Valuck, R.J.**, and Woodman, P.J. Care Options for the Veteran Patient: Treatment Options for Patients with Overactive Bladder. Treatment Guideline Pocket Card. American MECCA Publications, Fall 2000.

MacDiarmid, S., Lipsky, M., Granville, L., Newman, D., Woodman, P., and **Valuck, R.** A Primary Care Provider's Search for an Approach to Bladder Control Problems. Proceedings from an American MECCA Symposium on Bladder Control Problems, June 26, 1999, Chicago, IL. *Veterans Health System Journal* 2000; 5(5 Suppl.): 1-32.

E. Acknowledged Contributions to Published Works

Isaksen, S.F., Jonassen, J., Malone, D.C., et al. for the IMPROVE Investigators. Estimating Risk Factors for Patients with Potential Drug Related Problems Using Electronic Pharmacy Data. *Annals of Pharmacotherapy* 1999;33:406-412.

Malone, D.C., and Okano, G.J. Treatment of Urge Incontinence in Veterans Affairs Medical Centers. *Clinical Therapeutics* 1999; 21(5): 867-877.

Alsuwaiden, S., Malone, D.C., Billups, S.J., and Carter, B.L., for the IMPROVE Investigators. Characteristics of Ambulatory Care Clinics and Pharmacists in Veterans Affairs Medical Centers. *Am J Health-Syst Pharm* 1998; 55:68-72.

PRESENTATIONS

A. Invited

“Methods for Detecting Suicidality Outcomes in Observational Comparative Effectiveness and Safety Studies.” Presentation and Panel Discussion “Do Psychotropics Increase Suicide: Methodological Innovations for Making Sense of Conflicting Evidence.” Presented with Heather O. Anderson, Ph.D., at the NCDEU 51st Annual Meeting, Boca Raton, FL, June 15, 2011.

“Using Propensity Scores in Comparative Effectiveness Research.” Presented at the Colorado Health Outcomes (COHO) Program Research Methods and Statistics Discussion Series, Aurora, CO, October 13, 2010.

“Unintended Consequences of Drug Risk Communication: The Example of Antidepressants.” Presented at the RADARS System Annual Scientific Meeting, Bethesda, MD, April 14, 2010.

“Studying Drug Safety: From RCTs to CER.” Presentation and Panel Discussion at the American Statistical Association International Conference on Health Policy Statistics, Washington, D.C., January 21, 2010.

“Issues in Data Source Selection for Comparative Effectiveness Research.” Presented with Cynthia Kornegay, PhD, and others at the Agency for Healthcare Research and Quality (AHRQ) Annual Meeting, Bethesda, MD, September 15, 2009.

“Alternatives to RCTs: Ecological & Observational Designs and Emerging Data Systems for Next Generation Observational Studies.” Presented at the Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, Workshop on CNS Clinical Trials: Suicidality and Data Collection, Washington, D.C., June 16, 2009.

- “Emerging Data Systems for Next Generation Observational Studies of Antidepressants and Suicidality.” Presented at the International Suicidality Capstone Meeting: An Academia, Government, and Industry Forum (sponsored by: Columbia University, NIMH, AFSP, FDA, and CDC), New York Psychiatric Institute, New York, NY, January 27, 2009.
- “DARTNet (Distributed Ambulatory Research in Therapeutics Network): The Year in Review.” Presented with Wilson Pace, M.D., and David West, Ph.D., at the Agency for Healthcare Research and Quality (AHRQ), Bethesda, MD, December 12, 2008. Repeated later the same day at the Food and Drug Administration (FDA), Bethesda, MD.
- “Trends in the Management of Pharmaceutical Utilization and Expenditures in Managed Care: Lessons for Health Plans.” Presented at the Colorado Springs Health Partners Pharmacy and Therapeutics Committee Meeting, Colorado Springs, CO, August 22, 2007.
- “Effects of the FDA Black Box Warning on Antidepressants and Suicidality on Patterns of Care for Depression in the United States Managed Care Population.” Presented at the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) Meeting and Open Public Hearing, Bethesda, MD, December 13, 2006.
- “Application of Propensity Score Methods to Control for Bias in Observational Research.” Presented with Anne Libby, Ph.D., at the Colorado Health Outcomes (COHO) Program Brown Bag Lunch Series, Aurora, CO, July 13, 2006.
- “Ethical Issues in Drug Product Risk Assessment and Communication.” Presented with Elaine Morrato, DrPH at the First Western Pharmacoepidemiology and Drug Safety Conference, Napa, CA, October 7, 2005.
- “Bye Bye Books: Drug Information in Your Palm (Pilot) or Pocket (PC).” Presented as a Satellite Symposium at the American Pharmaceutical Association Annual Meeting, Orlando, FL, April 4, 2005.
- “Collaborative Research Opportunities in Medicaid.” Presented at The Medicaid Summit: Research on Prescription Benefits and Outcomes – An Invitational Cooperative Conference, Park City, UT, October 1, 2004.
- “Pharmaco-economic Evaluation to Inform Formulary Decision Making: Evaluating SSRI Antidepressants and Costs of Treating Side Effects through Decision Analytic Modeling.” Presented at the Institute for International Research (I.I.R.) Pharmacy Cost Management Summit, Chicago, IL, July 15, 2004.
- “Managing Risk for Psychiatric Medication Costs: Tools and Examples for Maximizing Value and Controlling the Drug Spend.” Presented at the Colorado Behavioral Health Coalition Pharmacy Management Educational Program, Beaver Creek, CO, June 10, 2004; repeated at: ValueOptions Medical Directors Summit, Colorado Springs, CO, July 30, 2004 and National PACE Alliance Annual Meeting, Denver, CO, October 23, 2005.

- "Biostatistics: Uses and Misuses." Presented at the Forest Laboratories Medical Science Liaison Winter Training Meeting, Orlando, FL, February 25, 2004.
- "PDAs PDQ." Presented at the National Community Pharmacists Association (NCPA) 105th Annual Convention & Trade Exposition, Seattle, WA, October 21, 2003.
- "Pharmacoeconomic Evaluation of Depression Treatment Strategies." Presented at a Satellite Breakfast Symposium on Value-Based Management & Treatment of Depression at the Academy of Managed Care Pharmacy (AMCP) Fall Educational Meeting, Montreal, Canada, October 17, 2003.
- "Pharmacoeconomic Considerations in the Management of Depression." Presented at a Roundtable Discussion on P&T Committee Considerations in the Management of Depression, at the 3rd Annual P&T Society Conference, Chicago, IL, May 28, 2003.
- "Pharmaceuticals: Ruthless Profiteering or Scapegoat?" Presented at the Colorado Healthcare Strategy & Management Breakfast Program, Denver, CO, April 25, 2003.
- "Current Trends in State Prescription Drug Monitoring Programs." Presented at the Colorado Prescription Drug Abuse Task Force Spring Biannual Luncheon and Meeting, Denver, CO, March 14, 2003. Repeated at CPDATF-sponsored Conference on Protecting Your License While Managing Pain, Colorado Springs, CO, November 14, 2003.
- "Pharmacoeconomics of Depression." Presented at Forest Pharmaceuticals Managed Care Advisory Board Meetings: Portland, OR, February 26, 2003; Seattle, WA, February 27, 2003; Boston, MA, May 3, 2003; and San Francisco, CA, June 21, 2003.
- "Handheld PC Use in the School of Pharmacy." Presented with Jeri Rome, I.T. Professional, at the University of Colorado School of Pharmacy, Denver, CO, January 23, 2003.
- "The Pharmacoeconomics of New Treatments for Depression: A Comparative Overview." Presented at Forest Pharmaceuticals Managed Care Pharmacy Advisory Board Meetings: San Francisco, CA, December 5, 2002; and Detroit, MI, December 19, 2002.
- "Need an Extra Hand? Using PDAs in Your Practice." Presented at the American Society of Consultant Pharmacists 33rd Annual Meeting, Anaheim, CA, November 14, 2002.
- "Current Trends in State Prescription Drug Monitoring Programs." Presented at the Colorado Pharmacists Society 2002 Annual Fall Meeting, Denver, CO, October 26, 2002.
- "The Pharmacoeconomic Impact of Treating Depression in Long Term Care." Presented at a Satellite Symposium on Contemporary Issues in the Diagnosis and Treatment of Late-Life Depression, at the American Medical Directors Association 2002 Annual Meeting, San Diego, CA, March 22, 2002.

- "Direct Costs of Treating Depression with Citalopram, SSRIs, and Venlafaxine in Managed Care." Presented at the Forest Pharmaceuticals Managed Care Pharmacy Advisory Board Meeting, New York, NY, June 22, 2001.
- "Evidence Based Medicine: Applications to Drug Studies." Presented at the ENT Resident Monthly Seminar, University of Colorado Health Sciences Center, June 7, 2001.
- "Regional Opportunities for Collaboration in Medicaid D.U.R.: Results from a Six-state HIV Pharmacotherapy Guideline Adherence Pilot Project." Presented at the 2001 Western DUR Conference, San Diego, CA, January 6, 2001.
- "From Assessment to Best Practices: Evaluation of Students' Online Learning." Presented at the 2000 AACP Annual Meeting, San Diego, CA, July 9, 2000.
- "An Introduction to Evidence Based Medicine." Presented at the Charleston (S.C.) Federal Pharmacists Association Summer CE Dinner Meeting, Charleston, SC, June 15, 2000.
- "The CliniMed System: Drug Use Management and Outcomes Research Software for the V.A. Medical System." Presented at the VISN18 Pharmacy Strategic Planning Conference, Scottsdale, AZ, April 2, 2000.
- "The Colorado Medicaid Antiretroviral DUR Project: Results and Implications for Provider and Patient Education." Presented with Jean Kutner, M.D., at the 2000 Western DUR Conference, Scottsdale, AZ, January 14, 2000.
- "Teaching with Technology: What are my Options?" Workshop speaker, Denison Memorial Library, University of Colorado Health Sciences Center, November 4, 1999.
- "An Introduction to Evidence Based Medicine." Presented at the Colorado Society of Health-System Pharmacists Annual Meeting, Denver, CO, October 14, 1999.
- "An Overview of Biostatistics." Presented at the Colorado Society of Health-System Pharmacists (CSHP) Annual Meeting, Denver, CO, October 14, 1999.
- "Beyond Acquisition Cost: Tools for Impact Assessment of New Drugs." Presented at the Federal Pharmacist Association of Michigan quarterly continuing education meeting, Dearborn, MI, September 16, 1999.
- "A Workshop on PC-based Data Analysis: Numbers Crunching by the Numbers." Presented with Gary Oderda, Pharm.D., at the Fourth Rocky Mountain Regional D.U.R. Symposium, Big Sky, MT, August 29, 1999.
- "Evidence Based Medicine Meets Pharmacy: Assessing the Quality of Drug-Drug Interaction Information." Presented at the University of Illinois at Chicago College of Pharmacy (graduate program seminar), March 11, 1999.

- "Methods for Assessing the Quality of Published Drug Studies." Presented at the Cook County (Chicago) Hospital Drug Use Evaluation Committee meeting, March 9, 1999; repeated at the University of Illinois at Chicago College of Pharmacy, March 11, 1999.
- "CliniMed: A Software System to Optimize Drug Use, Implement Guidelines, and Measure Outcomes in the VA Medical System." Presented with George Wortman, R.Ph., at the V.A. Formulary Managers National Meeting, San Antonio, TX, January 13, 1999.
- "Databases Available to Physicians in Management." Presented at the Louisville VA Medical Center—Clinical Use of Outcomes Studies Conference, Louisville, KY, December 10, 1998.
- "What I Learned (online) in School This Year..." Presented at the Teaching with Technology Mentors Program Brown Bag Lunch, UCHSC, October 27, 1998.
- "Tolterodine: An Example of Budget Impact Analysis." Presented at the Dallas-Fort Worth ACCP Educational Meeting, Dallas, TX, October 22, 1998.
- "Update on the Pharmacologic Management of Urinary Incontinence: Clinical and Economic Issues." Presented at the WellPoint Pharmacy Management Company, Pharmacy and Therapeutics Committee Meeting, Calabasas, CA, October 13, 1998.
- "Using Evidence Based Medicine to Improve the Quality of Drug-Drug Interaction Information." Presented at the Third Rocky Mountain Regional D.U.R. Symposium, Jackson, WY, August 31, 1998.
- "*Joe Faculty Online: My Experiences with Implementing Online Coursework in a Doctor of Pharmacy Program.*" Presented at the 1998 American Association of Colleges of Pharmacy Annual Meeting, Snowmass, CO, July 19, 1998.
- "Tolterodine: Its Budget Impact at the Systems Level." Presented at the Dallas VA Medical Center Pharmacy Clinical Staff Meeting, Dallas, TX, June 25, 1998.
- "Measuring Health Outcomes in Medicaid D.U.R. Programs." Presented at the Second Rocky Mountain Regional D.U.R. Symposium, Snowbird, UT, September 6, 1997.
- "Development, Implementation, and Evaluation of a Web-Based Course in *Evidence-Based Pharmacy Practice* Within the Doctor of Pharmacy Program." Presented at the 1997 Bridge to the Future Symposium, UCHSC, May 1, 1997.
- "Quasi-Experimental Designs in Health Services Research." Presented in Clinical Epidemiology Lecture Series, UCHSC, March 17, 1997; previously given January 23, 1996.
- "Academia and the Internet." Presented at The Rocky Mountain Biomedical Development Forum: Evolution of the Internet in Health Care, UCHSC, February 6, 1996.

"Defining the Boundaries of Appropriate Medical Care: Not Ready for Prime Time." Presented at monthly Health Services Research Grand Rounds, UCHSC, October 30, 1995.

"A Review of Biostatistics and Their Uses in the Nutrition Support Literature." Presented at the Colorado Society of Parenteral and Enteral Nutrition (CSPEN) Annual Meeting, Denver, CO, August 18, 1995.

"Issues in the Implementation of On-line, Prospective D.U.R.: Experiences from Illinois, Texas, and Colorado." Presented with Starlin Haydon-Greatting, M.S., and Curtis Burch, M.S., at the Sixth American D.U.R. Symposium, San Antonio, TX, February 17, 1995.

"An Introduction to Pharmacoeconomics and Outcomes Based Research." Presented with Daniel Malone, Ph.D. at the University of Colorado School of Pharmacy Preceptor Development and Continuing Education Program, Denver, CO, November 4, 1994.

"OBRA 1990 and D.U.R.: How Are We Doing?" Presented at the Colorado AHEC System Annual Meeting and Preceptor Conference, Snowmass, CO, October 2, 1994.

"The Home Health Care Model in the U.S.A.: Implications for Practitioners and Educators in Eastern Europe." Presented at the College of Veterinary and Pharmaceutical Sciences, Brno, Czechoslovakia, August 2, 1992.

B. Other presentations, refereed

"Rates of Coprescribing of Drugs with Potential for Drug-Drug Interactions among Persons Initiating Therapy with Selective Serotonin Reuptake Inhibitors." Presented with Christine Bagley, Pharm.D., and colleagues at the Society for General Internal Medicine (SGIM) 34th Annual Meeting, Phoenix, AZ, May 15, 2011.

"Off-Label Antidepressant Use in Children, Adolescents, and Young Adults." Presented with Angela Czaja, M.D., M.P.H. at the 2011 Epidemiologic Research Exchange, Colorado School of Public Health, Aurora, CO, April 8, 2011.

"Risk Factor Assessment of Venous Thromboembolism (VTE) in Critically Ill Children." Presented with Pamela Reiter, Pharm.D., at the Society of Critical Care Medicine (SCCM) 40th Critical Care Congress, San Diego, CA, January 19, 2011.

"Assessing the Effectiveness of Pharmacy-Based Adherence Interventions on Antiretroviral Adherence in Persons with the Human Immunodeficiency Virus (HIV)." Presented with Kevin Henderson, Pharm.D., and colleagues at the 45th ASHP Midyear Clinical Meeting, Anaheim, CA, December 7, 2010.

"Methods for Detecting Suicidality Outcomes in Observational Comparative Effectiveness and Safety Studies." Presented with Heather Anderson, Ph.D., at the 138th American Public Health Association (APHA) Annual Meeting, Denver, CO, November 9, 2010.

- “Prevalence of Co-occurring Mental Health Conditions among Opioid Misusers in a Commercially Insured Population.” Presented with Bryan Cochran, Ph.D., and colleagues at the 138th APHA Annual Meeting, Denver, CO, November 8, 2010.
- “Prescribing and Prescription Fill Patterns among Diagnosed Opioid Misusers and Other Opioid Users. Presented with Jill Van Den Bos, Ph.D., and colleagues at the Drug Information Association 46th Annual Meeting, Washington, D.C., June 15, 2010.
- “Studying Depression in DARTNet Primary Care Practices.” Presented with Anne Libby, Ph.D., at the Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Research (CER) Workshop II, Bethesda, MD, June 2, 2009.
- “Metabolic Testing Rates in Three State Medicaid Programs after FDA Warnings on Antipsychotic Drugs and Diabetes. Presented with Elaine Morrato, Dr.PH., and colleagues at the American Psychiatric Association 162nd Annual Meeting, San Francisco, CA, May 20, 2009.
- “Decline in Depression Treatment Persists After FDA Antidepressant Warnings.” Presented with Anne Libby, Ph.D., at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 11th Annual European Congress, Athens, Greece, November 11, 2008.
- “The Impact of Duloxetine, Venlafaxine, and Escitalopram Use and Prescription Copays on Medication Persistence, HEDIS Measures, and Expenditures.” Presented with Kavita Nair, Ph.D., at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual International Meeting, Toronto, Canada, May 5, 2008.
- "Rates and Characteristics of 10,000 Suicide Attempt Cases in Managed Care: An 8-Year Case Series, 1998-2005." Presented with Anne Libby, Ph.D., Robert Gibbons, Ph.D., Tami Benton, M.D., and Dwight Evans, M.D., at the American College of Neuropsychopharmacology (ACNP) 46th Annual Meeting, Boca Raton, FL, December 10, 2007.
- "Referral Patterns from Primary Care Providers to Specialty Mental Health Providers for New Episodes of Pediatric Depression, 1998-2005." Presented with Anne Libby, Ph.D., and Heather Orton, M.S., at the American College of Neuropsychopharmacology (ACNP) 46th Annual Meeting, Boca Raton, FL, December 10, 2007.
- “Serum Vitamin B12 Concentrations among Older Adults With and Without Use of Acid Suppressant Medications.” Presented with J. Mark Ruscin and colleagues at the American College of Clinical Pharmacy 2007 Annual Meeting, Denver, CO, October 16, 2007.
- "Antipsychotic Polypharmacy Costs and Compliance: A Five-State Medicaid Study." Presented with Elaine Morrato, Dr.PH., Sheri Dodd, M.S., and Richard Allen, M.S. at the 58th Institute on Psychiatric Services, New York, NY, October 6, 2006.

- "Antipsychotic and Metabolic Screening: A Four-State, Medicaid Study." Presented with Elaine Morrato, Dr.P.H., John Newcomer, M.D., and Richard Allen, M.S., at the 58th Institute on Psychiatric Services, New York, NY, October 5, 2006.
- "Evaluating the Impact of Pharmacy Experience, Scholastic Performance, Age, Education, and Self Review on Knowledge Retention and Clinical Confidence of Second Year Pharmacy Students." Presented with Connie Valdez, Pharm.D., and colleagues at the AACP 107th Annual Meeting, San Diego, CA, July 9-12, 2006.
- "Atypical Antipsychotics and Diabetes Testing: A Four-State Medicaid Study." Presented with Elaine Morrato, Dr.P.H., and colleagues at the American Diabetes Association's 66th Scientific Sessions, Washington, D.C., June 9-13, 2006.
- "Atypical Antipsychotics and Metabolic Screening: A Four-State Medicaid Study." Presented with Elaine Morrato, Dr.P.H., and colleagues at the American Psychiatric Association 159th Annual Meeting, Toronto, Canada, May 20-25, 2006.
- "Antipsychotic Utilization: A Six-State Medicaid Study." Presented with Elaine Morrato, Dr.P.H., Sheri Dodd, M.S., and Richard Allen, M.S. on behalf of the Medicaid Pharmacotherapy Research Consortium, at the American Psychiatric Association 159th Annual Meeting, Toronto, Canada, May 20-25, 2006.
- "Atypical Antipsychotic Treatment Patterns in Six Medicaid Fee-for-Service Populations." Presented with Elaine Morrato, Dr.P.H., Sheri Dodd, M.S., and Richard Allen, M.S. on behalf of the Medicaid Pharmacotherapy Research Consortium, at The Medicaid Summit, Park City, UT, September 29 - October 1, 2005.
- "Current Issues in Medicaid: Challenges and Future Directions." Presented with Fadia Shaya, Ph.D., M.P.H., and colleagues at the Academy of Managed Care Pharmacy (AMCP) 16th Annual Meeting & Showcase, San Francisco, CA, April 1, 2004.
- "Rates of Continuation of Non Formulary Medications for Chronic Disease Sufferers in Multi-tiered Pharmacy Benefit Plans." Presented with Kavita Nair, Ph.D., and Richard Allen, M.S., at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Eighth Annual International Meeting, Arlington, VA, May 20, 2003.
- "Gender Bias in the Use of Beta-Blocker Therapy in Heart Failure Patients: Report from the GRACE Study." Presented with Marianne McCollum, Ph.D., Robert L. Page, Pharm.D., and Kavita Nair, Ph.D. at the American College of Clinical Pharmacy (ACCP) 2003 Spring Practice and Research Forum, Palm Springs, CA, April 29, 2003.
- "Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals with Chronic Disease." Presented with Kavita A. Nair, Ph.D., and colleagues at the Academy of Managed Care Pharmacy (AMCP) 15th Annual Meeting, Minneapolis, MN, April 11, 2003.

- "Impact of Three-Tiered Pharmacy Benefit Plans on Member Satisfaction, Loyalty, and Willingness-to-Pay." Presented with Kavita A. Nair, Ph.D., Julie Ganther, Ph.D., Marianne McCollum, Ph.D., and Sonya J. Lewis, R.Ph. at the American Pharmaceutical Association 2003 Annual Meeting, New Orleans, LA, March 30, 2003.
- "Patterns of Hyperlipidemia Pharmacological Treatment in a Managed Care Organization." Presented with Setareh A. Williams, Ph.D., Marilyn MacArthur, Joseph J. Saseen, Pharm.D., Kavita Nair, Ph.D., Marianne McCollum, Ph.D., and Joe Ensor, Ph.D. at the 2002 ASHP Midyear Clinical Meeting, Atlanta, GA, December 11, 2002.
- "Determinants of Successful Outcome in Hyperlipidemia Management." Presented with Setareh A. Williams, Ph.D., Marilyn MacArthur, Joseph J. Saseen, Pharm.D., Kavita Nair, Ph.D., Marianne McCollum, Ph.D., and Joe Ensor, Ph.D. at the 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, D.C., October 13, 2002.
- "Impact of Multi-tiered Pharmacy Benefits on Patient Satisfaction." Presented with Kavita Nair, Ph.D., Julie Ganther, Ph.D., Marianne McCollum, Ph.D., and Sonya Lewis, R.Ph., at the Academy for Health Services Research and Health Policy (AHSR) Annual Meeting, Washington, D.C., June 23, 2002.
- "Impact of CHEST Guideline Adherence on Hospital Readmission Rates." Presented with Carole Tucker, Pharm.D., and Hanan Shaban, Pharm.D., D.M.S.A., at the Fifth Merck Pharmacy Student Research Conference - Western Region, Denver, CO, June 1, 2002.
- "Impact of Multi-tiered Pharmacy Benefits on Medication Adherence." Presented with Kavita Nair, Ph.D., Pamela Wolfe, M.S., Marianne McCollum, Ph.D., and Sonya Lewis, R.Ph., at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Seventh Annual International Meeting, Arlington, VA, May 20, 2002.
- "Impact of Multi-tiered Pharmacy Benefits on Patient Attitudes and Behavior." Presented with Kavita Nair, Ph.D., Pamela Wolfe, M.S., Julie Ganther, Ph.D., Marianne McCollum, Ph.D., and Sonya Lewis, R.Ph., at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Seventh Annual International Meeting, Arlington, VA, May 20, 2002.
- "Impact of Multi-tiered Pharmacy Benefits on Patient Attitudes Regarding Formulary and Nonformulary Medications." Presented with Kavita Nair, Ph.D., Julie Ganther, Ph.D., Marianne McCollum, Ph.D., and Sonya Lewis, R.Ph., at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting, Salt Lake City, UT, April 5, 2002.
- "Impact of Multi-tiered Pharmacy Benefits on Patient Attitudes." Presented with Kavita Nair, Ph.D., and colleagues at the American Pharmaceutical Association 2002 Annual Meeting, Philadelphia, PA, March 16, 2002.

- "Drug Selection, Dosing, and Utilization Patterns Among Depressed Patients Treated with SSRI's and Venlafaxine in U.S. Managed Care Plans." Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Fourth Annual European Congress, Cannes, France, November 11-12, 2001.
- "Patterns of Comorbidities and Coprescribing Among Depressed Patients Treated with SSRI's and Venlafaxine in U.S. Managed Care Plans." Presented at the ISPOR Fourth Annual European Congress, Cannes, France, November 11-12, 2001.
- "Direct Six-month Costs of Treating Depression with Citalopram, Fluoxetine, Paroxetine, Sertraline, and Venlafaxine in Managed Care." Presented at the Academy of Managed Care Pharmacy (AMCP) Fall Educational Meeting, Dallas, TX, October 19, 2001.
- "Indices for Evaluation of Drug Cost / Utilization: Every Silver Lining Has a Gray Cloud." Presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Sixth Annual International Meeting, Arlington, VA, May 22, 2001.
- "Ophthalmic β -blocker (OBB) Use in Patients with Obstructive Pulmonary Disease (OPD), Congestive Heart Failure (CHF), and Depression: Frequency Estimates from V.A. Hospitals." Presented with Jay I. Perlman, M.D., and colleagues at the Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, FL, May 3, 2001.
- "Evaluating Consumer Perceptions Towards Multi-Tiered Pharmacy Benefits: Preliminary Results." Presented with Kavita Nair, Ph.D. at the American Pharmaceutical Association 2001 Annual Meeting, San Francisco, CA, March 18-19, 2001.
- "Comparison of Direct Costs of Treating Depression with Citalopram, Fluoxetine, Paroxetine, Sertraline, and Venlafaxine." Presented at the American Medical Directors Association 2001 Annual Meeting, Atlanta, GA, March 15-17, 2001.
- "Cost-effectiveness of Pharmacist Conducted Patient Discharge Medication Teaching in a Rural Hospital." Presented with Karen Gorman, Pharm.D., at the American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas, NV, December 5, 2000.
- "A Cost-Benefit Analysis of the Employee Influenza Vaccine Program at the University of Colorado Hospital." Presented with Nancy Stolpman, Pharm.D., at the 11th Annual Rocky Mountain Research Symposium, Denver, CO, February 10, 2000.
- "A Survey of Faculty Perceptions of Internet-based Teaching Compared to Classroom Teaching." Presented with Debra Barnette, Pharm.D. et al. at the 1999 American Association of Colleges of Pharmacy Annual Meeting, Boston, MA, July 5, 1999.
- "A Comparison of Two Methods for Student Assessment of Instruction." Presented with Ralph J. Altieri, Ph.D., at the 1998 American Association of Colleges of Pharmacy Annual Meeting, Snowmass, CO, July 21, 1998.

- "Low-Normal Serum Vitamin B-12 Levels in a Geriatric Primary Care Setting." Presented with J. Mark Ruscin, Pharm.D., at the American Geriatrics Society / American Federation for Aging Research, 1998 Annual Scientific Meeting, Seattle, WA, May 9, 1998.
- "A Computerized Expert Prescribing System: Effect on Patient Care." Presented with Jeffrey Pickard, M.D., and colleagues at the Society of General Internal Medicine 21st Annual Meeting, Chicago, IL, April 24, 1998.
- "Chronic Gastric Acid Suppression and Vitamin B-12 Deficiency in Older Adults." Presented with J. Mark Ruscin, Pharm.D., at the American College of Clinical Pharmacy 1998 Spring Practice and Research Forum, Palm Springs, CA, April 7, 1998.
- "Which Factors Influence the Success of Human Erythropoietin in Premature Infants?" Presented with D. Patel, Pharm.D., P. Reiter, Pharm.D., and A. Rosenberg, M.D., at the ACCP 1998 Spring Practice and Research Forum, Palm Springs, CA, April 6, 1998.
- "Computerized Development of a Chronic Disease Indicator Score Using a Prescription Database." Presented with S. Billups, D. Malone, and B. Carter at the American Pharmaceutical Association Annual Meeting, Miami, FL, March 23, 1998.
- "PharmDs, PCs, and DRPs: Clinical Pharmacist versus Computer Detection of Drug-related Problems in Hospitalized Patients." Presented with Laura Borgelt, Pharm.D., and Jack Cavness, Pharm.D., at the American Society of Health-system Pharmacists Midyear Clinical Meeting, Atlanta, GA, December 9, 1997.
- "Using Computerized Decision Support to Promote Adherence to Drug Treatment Guidelines for Dyslipidemias in Veterans." Presented with George Wortman, R.Ph., at the Academy of Managed Care Pharmacy Annual Meeting, New Orleans, LA, May 10, 1997.
- "Identifying Patients at Risk for Drug-related Problems Using Automated Pharmacy Data." Presented with Daniel Malone, Ph.D., at the American Pharmaceutical Association Annual Meeting, Los Angeles, CA, March 10, 1997.
- "Utilizing the Drug Usage Evaluation Process to Guide Physician Education and Track Patient Outcome." Presented with Michael Mancano, Pharm.D., at the American Society of Health-system Pharmacists Midyear Clinical Meeting, New Orleans, LA, Dec. 11, 1996.
- "Factors Affecting Antibiotic Prescribing in a Managed Care Setting: An Exploratory Investigation." Presented with Bruce Lambert, Ph.D., at the American Public Health Association Annual Meeting, New York, NY, November 20, 1996.
- "Opening the Black Box: A Case Study of Conflicting Review Criteria." Presented at the 12th Annual Meeting of the International Society of Technology Assessment in Health Care (ISTAHC), San Francisco, CA, June 25, 1996.

"The Incidence of Psychoactive Drug Prescribing Problems: An Epidemiologic Estimate Using Prescription Claims Data." Presented at the 11th International Conference on Pharmacoepidemiology, Montreal, Quebec, Canada, August 29, 1995.

"The Effect of Regulatory Controls on the Quality of Psychoactive Drug Prescribing." Presented at the Third Wintergreen Research Conference in Social and Administrative Sciences in Pharmacy, Wintergreen, VA, October 15, 1994.

"Macro-level Screening Criteria to Identify Suboptimal Prescribers of Controlled Substances: A Report of Work in Progress." Presented at the 7th Social Pharmacy Workshop, Royal Holloway and Bedford New College, London, England, July 27, 1992.

"Development and Validation of Behaviorally-Anchored Rating Scales for Student Evaluation of Pharmacy Instruction." Presented with Paul Grussing, Ph.D. at the American Association of Colleges of Pharmacy 93rd Annual Meeting, Washington, D.C., July 14, 1992.

"Patent Medicine Fraud in Turn-of-the-century Muckraking Journalism: Fuel for the Fire of Progressive Reform." Presented at the 30th International Congress for the History of Pharmacy, Prague, Czechoslovakia, April 17, 1991.

"A Survey of State Pharmacy Association Publications." Presented at the American Association of Colleges of Pharmacy 91st Annual Meeting, Salt Lake City, UT, July 11, 1990.

PROFESSIONAL AFFILIATIONS

Academy of Managed Care Pharmacy (AMCP)

American Association of Colleges of Pharmacy (AACCP)

American Pharmacists Association (APhA)

Drug Information Association (DIA)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

International Society for Pharmacoepidemiology (ISPE)

PROFESSIONAL / ASSOCIATION SERVICE (current activity only)**A. Study Section Participation (grant reviewing)**

- 2011 - present Grant Reviewer, American Foundation for Suicide Prevention (AFSP)
- 2009 - present Member, Study Section (grant reviewer), Health Care Research and Training (HCRT) grants program, Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health (NIH).

B. Association Committee/Workgroup Service

- 2011 - present Scientific Advisor, American Foundation for Suicide Prevention (AFSP)
- 2009 - present Member, Methods Workgroup, Agency for Healthcare Research and Quality (AHRQ), National Institutes of Health, DEcIDE Program
- 2009 - present Member, Academic Council, International Society for Pharmacoepidemiology (ISPE)
- 2002 - present Member, *Risk Management* and *Medication Compliance* Special Interest Groups (SIGs), International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

C. Journal Service (Editorial Board membership and Manuscript reviewing)

- 2007 - present Member, International Editorial Advisory Board, and Reviewer, *Current Medical Research and Opinion*
- 2006 - present Reviewer, *American Journal of Psychiatry*
- 2006 - present Reviewer, *Archives of General Psychiatry*
- 2005 - present Reviewer, *Pharmacoepidemiology and Drug Safety*
- 2004 - present Reviewer, *American Journal of Managed Care*
- 2003 - present Reviewer, *Clinical Therapeutics*
- 2003 - 2009 Member, Editorial Advisory Board, *Journal of Managed Care Pharmacy*
- 2002 - present Reviewer (Gold List), *Journal of Managed Care Pharmacy*

AWARDS / HONORS

- 2011 *Sister Margaret Wright Graduate Award*, University of Illinois at Chicago, College of Pharmacy
- 2007 *Distinguished Investigator Award*, American Foundation for Suicide Prevention
- 2002 Selected to the Gold List of Peer Reviewers for the *Journal of Managed Care Pharmacy*
- 2001 Phi Lambda Sigma - Pharmacy Leadership Society, initiated February 8, 2001
- 2000 *Distinguished Service Award*, presented by the Colorado Prescription Drug Abuse Task Force at its Fall Biannual General Meeting, October 19, 2000
- 1998 *Outstanding Instructor Award*, presented by the graduating Doctor of Pharmacy class of 1998, UCHSC School of Pharmacy, May 22, 1998
- 1998 *UCHSC Bridge to the Future Innovation in Education Award*, May 1, 1998
- 1997 Selected as one of three 'Teaching with Technology Mentors' for the UCHSC School of Pharmacy, by the UCHSC Office of Education
- 1997 *Outstanding Instructor Award*, presented by the graduating Doctor of Pharmacy class of 1997, UCHSC School of Pharmacy, May 23, 1997
- 1995 *Rufus A. Lyman Award* (with P. Grussing and R. Williams) for outstanding article published in the American Journal of Pharmaceutical Education in 1994
- 1993 - 96 American Foundation for Pharmaceutical Education (AFPE) "Springboard to Teaching" Fellowship
- 1993 Rho Chi Pharmacy Honor Society, initiated February 15, 1993
- 1991 - 93 AFPE Procter & Gamble Fellowship in Pharmacoeconomics
- 1991 - 92 AFPE Josiah Kirkby Lilly Memorial Fellowship
- 1990 - 91 AFPE Graduate Fellowship in Pharmacy Administration
- 1985 *Merck Award for Scholastic Achievement*, UCHSC School of Pharmacy
- 1982 - 84 University of Colorado Regent Scholarship

UNIVERSITY SERVICE**A. School of Pharmacy (SOP) Committees, current**

- 2011 - present Chair, Appointment, Reappointment and Tenure (ARPT) Committee,
Department of Clinical Pharmacy (DOCP)
- 2008 - present Chair, Student Ethics and Conduct Code (SECC) Committee

B. Campus Level (UCD/AMC) Committees, current

- 2006 - present Member, Information Technology Policy Group, UCD/AMC

C. Other / Previous Committees (past 3 years only)

- 2010 - 2011 Member, Appointment, Reappointment and Tenure (ARPT) Committee,
Department of Clinical Pharmacy (DOCP)
- 2009 - 2010 Chair, Search Committee, Pharmaceutical Outcomes Research Faculty
Member, Department of Clinical Pharmacy (DOCP)
- 2008 - 2009 Member, ACPE Self Study Committee (Curriculum & Assessment
subcommittee), SOP
- 2008 - 2009 Member, Search Committee, Director of SOP Office of Postgraduate
Professional Education (OPPE)
- 2007 - 2010 Member, Building Oversight Committee, Skaggs School of Pharmacy
and Pharmaceutical Sciences, Anschutz Medical Campus, Aurora, CO
- 2006 - 2010 Member, Postgraduate Professional Education Committee

PROFESSIONAL DEVELOPMENT ACTIVITIES

- 2010 - 2011 Colorado Mentoring Training (CO-MENTOR) program, Colorado Clinical and Translational Sciences Institute (CCTSI), Class of 2011
- 2009 - 2010 Leadership in Innovative Team Science (LITeS) program, Colorado Clinical and Translational Sciences Institute (CCTSI), Class of 2010
- 2009 - present Member, Colorado Clinical and Translational Sciences Institute (CCTSI)
- 2002 - 2003 University of Colorado Emerging Leaders Program (ELP), Class of 2003

COMMUNITY SERVICE (current activity only)

- 2010 - present Member, Board of Directors, The America Cup International Fly Fishing Tournament, Vail, CO
- 2009 - present President, Colorado Prescription Drug Abuse Task Force, Denver, CO (Member of Task Force since 1998; Board of Directors since 2000; Vice President from 2007-2009; President since 2009; helped organize the Colorado Prescription Drug Abuse Summit, November 10, 2011 on University of Colorado Anschutz Medical Campus).

REFERENCES

Available upon request.

(rjv.cv.011812)